MA42048A - Dérivés d'aminoesters - Google Patents

Dérivés d'aminoesters

Info

Publication number
MA42048A
MA42048A MA042048A MA42048A MA42048A MA 42048 A MA42048 A MA 42048A MA 042048 A MA042048 A MA 042048A MA 42048 A MA42048 A MA 42048A MA 42048 A MA42048 A MA 42048A
Authority
MA
Morocco
Prior art keywords
aminoesters
derivatives
aminoesters derivatives
Prior art date
Application number
MA042048A
Other languages
English (en)
Inventor
Gabriele Amari
Elisabetta Armani
Charles Baker-Glenn
Wesley Blackaby
Naimisha Trivedi
De Pöel Hervé Van
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA42048A publication Critical patent/MA42048A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA042048A 2015-05-07 2016-05-05 Dérivés d'aminoesters MA42048A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15166703 2015-05-07

Publications (1)

Publication Number Publication Date
MA42048A true MA42048A (fr) 2018-03-14

Family

ID=53177142

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042048A MA42048A (fr) 2015-05-07 2016-05-05 Dérivés d'aminoesters

Country Status (5)

Country Link
US (2) US9809582B2 (fr)
EP (1) EP3292118A1 (fr)
AR (1) AR104532A1 (fr)
MA (1) MA42048A (fr)
WO (1) WO2016177849A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111161344B (zh) * 2019-12-31 2021-08-10 广州永士达医疗科技有限责任公司 基于oct设备的气道弹性测量方法、系统、设备及介质
FI20225388A1 (en) 2022-05-05 2023-11-06 Equinorm Ltd New heterocyclic compounds, preparation methods and their uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086676A1 (es) * 2011-06-06 2014-01-15 Chiesi Farma Spa Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de fosfodiesterasa
HK1213245A1 (zh) 2012-12-05 2016-06-30 奇斯药制品公司 作为pde4抑制剂的苯乙基吡啶衍生物
HK1212988A1 (zh) 2012-12-05 2016-07-22 奇斯药制品公司 作为pde-4抑制剂的苯基乙基吡啶衍生物
WO2014086852A1 (fr) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Dérivés de phényléthylpyridine comme inhibiteurs de pde4
RU2016121852A (ru) 2013-12-05 2017-12-07 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные бензгидрила для лечения респираторных заболеваний
US9133185B2 (en) * 2013-12-05 2015-09-15 Chiesi Farmaceutici S.P.A Heteroaryl derivatives
US9763924B2 (en) 2014-06-05 2017-09-19 Chiesi Farmaceutici S.P.A. Aminoester derivatives
US9326976B2 (en) 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives

Also Published As

Publication number Publication date
US20160326147A1 (en) 2016-11-10
WO2016177849A1 (fr) 2016-11-10
US20180016265A1 (en) 2018-01-18
AR104532A1 (es) 2017-07-26
US9809582B2 (en) 2017-11-07
EP3292118A1 (fr) 2018-03-14

Similar Documents

Publication Publication Date Title
IL268697A (en) Formulations
DK3688162T3 (da) Formuleringer
EP3513809A4 (fr) Composition médicinale
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
DK3529248T3 (da) Farmaceutiske sammensætninger
PT4070788T (pt) Formulações farmacêuticas
BR112017027227A2 (pt) Agente anti-câncer
EP3426242A4 (fr) Icaritine et dérivés d'icaritine
LT3402792T (lt) Chinolin-2-ono dariniai
LT3457851T (lt) Sobetiromo dariniai
IL281425A (en) Nanoparticle formulations
EP3283171A4 (fr) Dérivés d'amphotéricine b
LT3371168T (lt) Indolin-2-ono dariniai
EP3541200C0 (fr) Formulations pulvérulentes
EP3536734A4 (fr) Composition polymérisable
EP3127914C0 (fr) Dérivés d'adrénomédulline à action prolongée
IL251859A0 (en) Methotrexate formulation
EP3454847A4 (fr) Formulations de médicaments améliorées
EP3431808A4 (fr) Butée d'arrêt
HUE054815T2 (hu) 3,5-Difenil-diazol vegyületek vízoldható származékai
HUE063178T2 (hu) Kopanlizib formulációi
DK3280447T3 (da) Farmaceutiske formuleringer
IL272167A (en) Hemopexin formulations
EP3444345A4 (fr) Dérivé d'arnmicro-143
DK3645513T3 (da) Benzazepinderivater